JNJ-5207787 | Neuropeptide Y Y2 Receptor

Cas No.:	683746-68-1
Chemical Name:	JNJ 5207787
Synonyms:	JNJ 5207787;(E)-N-(1-acetyl-2,3-dihydroindol-6-yl)-3-(3-cyanophenyl)-N-[1-(2-cyclopentylethyl)piperidin-4-yl]prop-2-enamide;JNJ-5207787;SCHEMBL4839776;GTPL3504;JNJ-5207787 hydrochloride;UNII-OW44B6FA0Y;BDBM50140506;G14051;SCHEMBL4839763;HY-107732;GLXC-02307;GLXC-15741;NCGC00371015-01;(E)-N-(1-acetyl-2,3-dihydroindol-6-yl)-3-(3-cyanophenyl)-N-(1-(2-cyclopentylethyl)piperidin-4-yl)prop-2-enamide;(E)-N-(1-acetylindolin-6-yl)-3-(3-cyanophenyl)-N-(1-(2-cyclopentylethyl)piperidin-4-yl)acrylamide;JNJ5207787;(E)-N-(1-Acetyl-2,3-dihydro-1H-indol-6-yl)-3-(3-cyano-phenyl)-N-[1-(2-cyclopentyl-ethyl)-piperidin-4-yl]-acrylamide;(2E)-N-(1-Acetyl-2,3-dihydro-1H-indol-6-yl)-3-(3-cyanophenyl)-N-[1-(2-cyclopentylethyl)-4-piperidinyl]-2-propenamide;EX-A7781;Q27893043;BCP9000802;OW44B6FA0Y;683746-68-1;683746-68-1 (free base);N-(1-Acetyl-2,3-dihydro-1H-indol-6-yl)-3-(3-cyano-phenyl)-N-(1-(2-cyclopentyl-ethyl)-piperidin-4yl)acrylamide;DTXSID60438082;trans-N-(1-Acetyl-2,3-dihydro-1H-indol-6-yl)-3-(3-cyanophenyl)-N-(1-(2-cyclopentylethyl)piperidin-4-yl)acrylamide;N-(1-Acetyl-2,3-dihydro-1H-indol-6-yl)-3-(3-cyanophenyl)-N-[1-(2-cyclopentyl-ethyl)-piperidin-4yl]acrylamide hydrochloride;CHEMBL21283;CS-0029400;AKOS024457931;2-Propenamide, N-(1-acetyl-2,3-dihydro-1H-indol-6-yl)-3-(3-cyanophenyl)-N-(1-(2-cyclopentylethyl)-4-piperidinyl)-, (2E)-;DTXCID30388904;ICB74668
SMILES:	CC(=O)N1CCC2=C1C=C(C=C2)N(C3CCN(CC3)CCC4CCCC4)C(=O)C=CC5=CC(=CC=C5)C#N
Formula:	C₃₂H₃₈N₄O₂
M.Wt:	510.669727802277
Purity:	>98%
Sotrage:	2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO

Cat. No.	Product name	Field of application
DC60812	SHA 68	SHA 68 is a potent and selective non-peptide neuropeptide S receptor (NPSR) antagonist with IC50s of 22.0 and 23.8 nM for NPSR Asn107 and NPSR Ile107, respectively. SHA 68 has limited the blood-brain barrier (BBB) penetration and the activity in neuralgia.
DC28209	JNJ-5207787	JNJ-5207787 represents a breakthrough in neuropeptide Y receptor modulation as a brain-penetrant, selective Y2 receptor antagonist.
DC11386	NNZ-2591	NNZ2591 (cyclo-L-glycyl-L-2-allylproline)1 is an investigational synthetic analog of cyclic glycine-proline (cGP), a breakdown product of human insulin-like growth factor 1 (IGF-1), that has been chemically modified to increase its half-life, stability, and oral bioavailability.